Zytovision

Telefon: 08140 67753

E-Mail

www.zytovision.de

Webseite

den obigen Link klicken, werden Sie auf eine Website zu nehmen, die nicht von Hotfrog betrieben wird. Hotfrog ist nicht verantwortlich für den Inhalt oder die Verfügbarkeit der verknüpften Seiten.
Adresse: Fischkai 1Bremerhaven27572

Zytovision
Kategorien: Unknown

Key Kontaktdaten zu Zytovision
Telefon
08140 67753
Email
E-Mail
Webseite
www.zytovision.de
Adresse
Fischkai 1, Bremerhaven, 27572
 

Molecular Diagnostics

Firmenprofil

The ZytoLight SPEC ALK/EML4 TriCheck™ Probe is designed to detect inversions involving the chromosomal region 2p23.1-p23.2 harboring the ALK gene and the chromosomal region 2p21 harboring the EML4 gene by FISH (Fluorescence in situ Hybridization). Moreover, using this probe it is possible to discriminate between EML4-ALK inversions and translocations affecting ALK, but not EML4, such as ALK-TGF or ALK-KIF5B translocations. Inversions in the short arm of chromosome 2 [inv(2)(p21p23)] have been frequently detected in non-small cell lung cancer (NSCLC) and lead to the formation of EML4-ALK fusion transcripts. A few reports also identified EML4-ALK fusion transcripts in breast, gastric, and colorectal cancers. ALK kinase targeted therapies may represent a very effective therapeutic strategy in NSCLC patients carrying EML4-ALK rearrangements. For the detection of this subset of NSCLC patients, the specific detection of EML4-ALK rearrangements using Fluorescence in situ Hybridization is a helpful tool for diagnosis and for selecting treatment

  • Firmenprofil

    The ZytoLight SPEC ALK/EML4 TriCheck™ Probe is designed to detect inversions involving the chromosomal region 2p23.1-p23.2 harboring the ALK gene and the chromosomal region 2p21 harboring the EML4 gene by FISH (Fluorescence in situ Hybridization). Moreover, using this probe it is possible to discriminate between EML4-ALK inversions and translocations affecting ALK, but not EML4, such as ALK-TGF or ALK-KIF5B translocations. Inversions in the short arm of chromosome 2 [inv(2)(p21p23)] have been frequently detected in non-small cell lung cancer (NSCLC) and lead to the formation of EML4-ALK fusion transcripts. A few reports also identified EML4-ALK fusion transcripts in breast, gastric, and colorectal cancers. ALK kinase targeted therapies may represent a very effective therapeutic strategy in NSCLC patients carrying EML4-ALK rearrangements. For the detection of this subset of NSCLC patients, the specific detection of EML4-ALK rearrangements using Fluorescence in situ Hybridization is a helpful tool for diagnosis and for selecting treatment

Zytovision's Keywords

Molecular Diagnostics